New pill could cut recurrence risk in aggressive breast cancer
NCT ID NCT04254263
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can lower the risk of cancer coming back in women with HER2-positive breast cancer who still have cancer cells after initial treatment. About 316 women will take pyrotinib daily for a year. Researchers will track how long participants stay cancer-free and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pyrotinib (a targeted cancer drug taken as a pill once daily for one year, combined with trastuzumab)
- What this could lead to
- If successful, this could offer a new option to lower the chance of breast cancer returning in patients who still have cancer cells after initial chemotherapy and targeted therapy.
- What could go wrong
- This is a phase 3 trial, but it is still recruiting and results are not yet known. The drug may cause side effects, and it is unclear if it will be more effective than current standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 200127, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?